The manufacturer says that in looking to a possible future launch of its Bonolive ingredient in the US, Japan and Spain, it will be extending a collaboration with raw material supplier Ferrer Grupo to jointly promote the product as well.
Hans van der Saag, managing director for BioActor, told NutraIngredients.com that the patented product would allow it to launch into the olive-based polyphenol market, which the company claims remains relatively untapped for manufacturers.
In looking to bolster interest in the product, van der Saag said the company was already working with selected processors on introducing the products into formulations.
The manufacturer claimed that the Bonolive product was expected to have interesting applications for beverages as a result of being highly soluble.
With product testing ongoing, BioActor said that it had not yet set a potential date for launching the product as it continued to wait on clinical research into potential bone health benefits from the ingredient.
“We are very much approaching the launch from an efficacy stand point,” said van der Saag. “The use of olive polyphenol is not yet an established market.”
The manufacturer says that in attempting to push itself into the market, the collaboration would also extend to clinical research and backing for any possible health claims attached to Bonolive.
A human trial of the product has already begun on 80 volunteer tests subjects and is expected to be completed within twelve months, according to the company.
Van der Saag says obtaining possible backing from this research for bone health claims is likely to be a key part of the launch as well as meeting European Food Safety Authority (EFSA) regulations.
“Bonolive presents a unique opportunity to expand the functionality of bone health products,” he stated. “It targets the underlying inflammatory processes that lead to osteoporosis and is especially important in age related osteoporosis in both men and women.”